(Q37022464)

17 August 2017

1 reference

title

Part II: management of resistance to imatinib in chronic myeloid leukaemia (English)

1 reference

17 August 2017

1 reference

1 reference

Jane F Apperley

1

1 reference

17 August 2017

publication date

1 December 2007

1 reference

Lancet Oncology Commission

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

12

1 reference

17 August 2017

page(s)

1116-1128

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Imatinib and regression of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

BCR-ABL mutant kinetics in CML patients treated with dasatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Allosteric inhibitors of Bcr-abl-dependent cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Drug resistance in cancer: principles of emergence and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970379-0

7 January 2021

10.1016/S1470-2045(07)70379-0

Identifiers

DOI

1 reference

17 August 2017

1 reference